Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
Gazinska P, Milton C, Iacovacci J, Ward J, Buus R, Alaguthurai T, Graham R, Akarca A, Lips E, Naidoo K, Wesseling J, Marafioti T, Cheang M, Gillett C, Wu Y, Khan A, Melcher A, Salgado R, Dowsett M, Tutt A, Roxanis I, Haider S, Irshad S. Gazinska P, et al. Among authors: gillett c. Clin Cancer Res. 2022 Oct 14;28(20):4494-4508. doi: 10.1158/1078-0432.CCR-22-0543. Clin Cancer Res. 2022. PMID: 36161312 Free PMC article.
BRCA1 dysfunction in sporadic basal-like breast cancer.
Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN. Turner NC, et al. Among authors: gillett ce. Oncogene. 2007 Mar 29;26(14):2126-32. doi: 10.1038/sj.onc.1210014. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016441
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F. Tutt A, et al. Among authors: gillett c. BMC Cancer. 2008 Nov 21;8:339. doi: 10.1186/1471-2407-8-339. BMC Cancer. 2008. PMID: 19025599 Free PMC article.
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. Turner N, et al. Among authors: gillett c. Cancer Res. 2010 Mar 1;70(5):2085-94. doi: 10.1158/0008-5472.CAN-09-3746. Epub 2010 Feb 23. Cancer Res. 2010. PMID: 20179196 Free PMC article.
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. Loi S, et al. Among authors: gillett ce. Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13. doi: 10.1073/pnas.0907011107. Epub 2010 May 17. Proc Natl Acad Sci U S A. 2010. PMID: 20479250 Free PMC article.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Esserman LJ, et al. Among authors: gillett ce. Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20. Breast Cancer Res Treat. 2011. PMID: 21597921 Free PMC article.
197 results